Drug discovery company Insilico Medicine has entered a research collaboration with pharmaceutical giant Eli Lilly to advance AI-driven drug discovery. 

Insilico will use its validated Pharma.AI platform to generate, design, and optimise candidate compounds against targets defined under the agreement.  

The company is eligible to receive over $100 million including upfront, milestone payments and tiered royalties on net sales upon commercialisation of any resulting drug products.  

“We are delighted to collaborate with Lilly, a global leader in the pharmaceutical industry, renowned for its commitment to medical innovation,” said Alex Zhavoronkov, Founder and Co-CEO of Insilico Medicine.  

“Lilly has been a valued user of our Pharma.AI software suite, and this expanded collaboration further recognises Insilico’s AI-driven drug discovery capabilities while strengthening our longstanding partnership.  

“By joining forces, we are accelerating the development of transformative therapies to address urgent patient needs worldwide.” 

This latest collaboration follows an earlier partnership between the two companies in 2023 over AI-based software licensing. 

 

Bruno Quinney, Content Team, DDW